Search

Displaying results 2641 - 2650 of 7540 in total
  1. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated for the treatment of patients with Pompe disease, a rare inherited metabolic disorder characterized by … Cipaglucosidase alfa is conjugated with mannose-6-phosphate (M6P) N-glycans that bind to the cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle, one of the main affected tissues

  2. Drug

    Etonogestrel

    go.drugbank.com/drugs/DB00294
    ApprovedInvestigational

    [A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]

  3. Drug

    Exemestane

    go.drugbank.com/drugs/DB00990
    ApprovedInvestigational

    It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.

  4. Drug

    Lenograstim

    go.drugbank.com/drugs/DB13144
    ApprovedWithdrawn

    Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.

  5. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway. … progression on at least one line of endocrine therapy.

  6. Drug

    Teriflunomide

    go.drugbank.com/drugs/DB08880
    ApprovedInvestigational

    Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis.

    Categories: Analgesics, Non-Narcotic
  7. Drug

    Benactyzine

    go.drugbank.com/drugs/DB09023
    ApprovedWithdrawn

    Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.

  8. Drug

    Nipocalimab

    go.drugbank.com/drugs/DB16257
    ApprovedInvestigational

    [L64042] It is administered by intravenous infusion.[L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis. … Nipocalimab-aahu is a neonatal Fc receptor (FcRn) blocker used to treat certain antibody-mediated autoimmune diseases.

  9. Drug

    Lubiprostone

    go.drugbank.com/drugs/DB01046
    ApprovedInvestigational

    A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells.

  10. Drug

    Amineptine

    go.drugbank.com/drugs/DB04836
    ApprovedIllicitWithdrawn

    The Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until

    Categories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome